SEATTLE, Nov. 3 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals Inc. (Nasdaq: TRBN) today announced that it plans to issue earnings results for the third quarter and nine months ended Sept. 30, 2008, after the close of market on Nov. 10, 2008. The company's earnings conference call will take place Nov. 10, 2008, at 2 p.m. PST (5 p.m. EST).
Both live events will be available for viewing on Trubion's website at http://investors.trubion.com/events.cfm.
Third-Quarter and Nine Months Earnings Conference Call: 2 p.m. PST/5 p.m. EST, Nov. 10, 2008
Trubion will host a conference call and webcast to discuss its third-quarter and nine months 2008 financial results. The call will be held Nov. 10 at 2 p.m. PST (5 p.m. EST). The live event will be available on Trubion's website at http://investors.trubion.com/events.cfm, or by calling (877) 440-5804 or (719) 325-4881. A replay of the discussion will be available beginning the evening of Nov. 10 on Trubion's website or by calling (888) 203-1112 or (719) 457-0820, and entering 8489656. The telephone replay will be available through Nov. 17, 2008.
Trubion is a biopharmaceutical company that is creating a pipeline of novel protein therapeutic product candidates to treat autoimmune and inflammatory diseases and cancer. The company's mission is to develop a variety of first-in-class and best-in-class product candidates, customized for optimal safety, efficacy, and convenience that it believes may offer improved patient experiences. Trubion's current product candidates are novel single-chain protein, or SMIP(TM), therapeutics, and are designed using its custom drug assembly technology. Trubion's product pipeline includes CD20-directed SMIP therapeutics such as TRU-015 and SBI-087 for autoimmune and inflammatory diseases, developed under the company's Wyeth collaboration. Trubion's product pipeline also includes Trubion's proprietary product candidate, TRU-016, a novel CD37-targeted therapy for the treatment of B-cell malignancies that is currently in Phase 1/2 clinical evaluation. In addition to Trubion's current clinical stage product pipeline, the company is also developing additional product candidates that build on its product development experience. More information is available in the investors section of Trubion's website: http://investors.trubion.com.
Senior Director, Corporate Communications
Trubion Pharmaceuticals Inc.
Waggener Edstrom Worldwide Healthcare
Senior Vice President
|SOURCE Trubion Pharmaceuticals Inc.|
Copyright©2008 PR Newswire.
All rights reserved